Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Increasing evidence strongly suggests that bevacizumab compound impacts the immunological signature of cancer patients and normalizes tumor vasculature. This study aims to investigate the correlation between the clinical response to bevacizumab-based chemotherapy and the improvement of immune fitness of multi-treated ovarian cancer patients. Peripheral blood mononuclear cells (PBMCs) of 20 consecutive recurrent ovarian cancer patients retrospectively selected to have received bevacizumab or non-bevacizumab-based chemotherapy (Bev group and Ctrl group, respectively) were analyzed. CD4, CD8, and regulatory T cell (Treg) subsets were monitored at the beginning (T0) and after three and six cycles of treatment, together with IL10 production. A lower activated and resting Treg subset was found in the Bev group compared with the Ctrl group until the third therapy cycle, suggesting a reduced immunosuppressive signature. Indeed, clinically responding patients in the Bev group showed a high percentage of non-suppressive Treg and a significant lower IL10 production compared with non-responding patients in the Bev group after three cycles. Furthermore, clinically responding patients showed a discrete population of effector T cell at T0 independent of the therapeutic regimen. This subset was maintained throughout the therapy in only the Bev group. This study evidences that bevacizumab could affect the clinical response of cancer patients, reducing the percentage of Treg and sustaining the circulation of the effector T cells. Results also provide a first rationale regarding the positive immunologic synergism of combining bevacizumab with immunotherapy in multi-treated ovarian cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“increased tumor infiltration by activated TEFF cells coupled to TREG (and TAM) depletion”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Napoletano et al., 2019
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · cited 1×
“Ovarian cancer still accounts for the highest mortality rate among all gynecological malignancies, with 295,414 estimated new cases and 184,799 estimated new deaths in 2018 worldwide [1].”
BackgroundNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Miyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291 · cited 3×
“aTreg have been described as terminally differentiated cells that rapidly die after exerting their suppressive activity, whereas rTreg proliferate and convert into aTreg both in vitro and in vivo [10].”
BackgroundInfluentialGabrilovich, D. I., Chen, H. L., Girgis, K. R., Cunningham, H. T., Meny, G. M., Nadaf, S., Kavanaugh, D., & Carbone, D. P. (1996) · Nature Medicine · doi:10.1038/nm1096-1096 · Cited by 1,977
Immunological aspects of cancer chemotherapy
Zitvogel, L., Apetoh, L., Ghiringhelli, F., & Kroemer, G. (2008) · Nature Reviews Immunology · doi:10.1038/nri2216 · Cited by 1,712 · cited 1×
“) that differently impact the immunological system [29], together with the capacity of the immunological signature of each patient to differently respond to the same environmental factor, such as chemotherapy and surgery.”
BackgroundNormalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605 · cited 2×
“Indeed, it is reasonable to suggest that the circulating effector T cells recruited and sustained by bevacizumab treatment, thanks to its ability to restore tumor microvascular normalization [13], could be expanded by the administration of checkpoint inhibitor agents, thus giving a strong biological rationale for the…”
BackgroundTumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Gabrilovich, D., Ishida, T., Oyama, T., Ran, S., Kravtsov, V., Nadaf, S., & Carbone, D. P. (1998) · Blood · doi:10.1182/blood.v92.11.4150 · Cited by 1,048
Dynamics of T Lymphocyte Responses: Intermediates, Effectors, and Memory Cells
Lanzavecchia, A., & Sallusto, F. (2000) · Science · doi:10.1126/science.290.5489.92 · Cited by 796 · cited 1×
“CD8 lymphocytes exerted their cytotoxic activity by eliminating tumor cells, while CD4 T lymphocytes sustained and maintained a CD8 T cell response by cytokine production [9].”
BackgroundRay-Coquard, I., Cropet, C., Van Glabbeke, M., Sebban, C., Le Cesne, A., Judson, I., Tredan, O., Verweij, J., Biron, P., Labidi, I., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3845 · Cited by 784 · cited 1×
“Another important point is the occurrence of leukopenia in multi-treated patients, which represents an important prognostic factor in patients with advance malignances [30].”
BackgroundWallin, J. J., Bendell, J. C., Funke, R., Sznol, M., Korski, K., Jones, S., Hernandez, G., Mier, J., He, X., Hodi, F. S., et al. (2016) · Nature Communications · doi:10.1038/ncomms12624 · Cited by 713 · cited 1×
“Trafficking lymphocytes also increased in tumors following bevacizumab and combination treatment [26].”
BackgroundTerme, M., Pernot, S., Marcheteau, E., Sandoval, F., Benhamouda, N., Colussi, O., Dubreuil, O., Carpentier, A. F., Tartour, E., & Taieb, J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-2325 · Cited by 684 · cited 1×
“Several authors have shown the immune effects of bevacizumab in multiple cancer settings, such as decrease in patients’ regulatory T cells (Tregs) [3,4] and expansion of B and T cells [2].”
BackgroundChemotherapy Use, Performance Status, and Quality of Life at the End of Life
Prigerson, H. G., Bao, Y., Shah, M. A., Paulk, M. E., LeBlanc, T. W., Schneider, B. J., Garrido, M. M., Reid, M. C., Berlin, D. A., Adelson, K. B., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2378 · Cited by 645
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L. D., Carbone, D. P., & Gabrilovich, D. I. (1998) · PubMed · Cited by 530
Oyama, T., Ran, S., Ishida, T., Nadaf, S., Kerr, L., Carbone, D. P., & Gabrilovich, D. I. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.3.1224 · Cited by 481
Li, B., Lalani, A. S., Harding, T. C., Luan, B., Koprivnikar, K., Huan Tu, G., Prell, R., VanRoey, M. J., Simmons, A. D., & Jooss, K. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1558 · Cited by 232 · cited 1×
“In particular, three different mechanisms related to VEGF-mediated immunosuppression have been assessed so far: inhibition of dendritic cell maturation [19–21], reduction of T cell tumor infiltration [22], and promotion of inhibitory cells in the tumor microenvironment [23].”
Background和田, 純., Suzuki, H. Y., Fuchino, R., Yamasaki, A., Nagai, S., Yanai, K., Koga, K., Nakamura, M., Tanaka, M., Morisaki, T., et al. (2009) · PubMed · Cited by 197
Immunomodulatory Activity of VEGF in Cancer
(2017) · International Review of Cell and Molecular Biology · doi:10.1016/bs.ircmb.2016.09.007 · Cited by 194 · cited 1×
“The effects of bevacizumab on patients’ immune system are still not completely elucidated, although a strong rationale about the interplay between its ligand (VEGF) and the host’s immune response suppression has already been shown [18].”
BackgroundCD4 + CD25 + regulatory T cells in tumor immunity
Chen, X., Du, Y., Lin, X., Qian, Y., Zhou, T., & Huang, Z. (2016) · International Immunopharmacology · doi:10.1016/j.intimp.2016.03.009 · Cited by 159
Shou, J., Zhang, Z., Lai, Y., Chen, Z., & Huang, J. (2016) · BMC Cancer · doi:10.1186/s12885-016-2732-0 · Cited by 144
Kobold, S., Hegewisch‐Becker, S., Oechsle, K., Jordan, K., Bokemeyer, C., & Atanackovic, D. (2009) · The Oncologist · doi:10.1634/theoncologist.2009-0109 · Cited by 109 · cited 2×
“bevacizumab 5 mg/kg every 21 days immediately after paracentesis for treatment of malignant ascites [5,6] plus intravenous (intravenous injection, i.”
BackgroundMethodImmunological Effects of Bevacizumab-Based Treatment in Metastatic Colorectal Cancer
Manzoni, M., Rovati, B., Ronzoni, M., Loupakis, F., Mariucci, S., Ricci, V., Gattoni, E., Salvatore, L., Tinelli, C., Villa, E., et al. (2010) · Oncology · doi:10.1159/000320609 · Cited by 92 · cited 3×
“We also showed that responding bevacizumab-treated patients reported a higher percentage of circulating CD4 effector T cells compared with nonresponding bevacizumab patients, confirming what has already been observed in metastatic colorectal cancer [2].”
BackgroundResultNuclear Factor-κB in Immunity and Inflammation: The Treg and Th17 Connection
Ruan, Q., & Chen, Y. H. (2011) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-0106-3_12 · Cited by 87 · cited 1×
“Because IL10, such as TGFβ, is one of the most important cytokines released by Tregs [14] that is able to downregulate Th1 cytokine production and block NF-κB activity [15], T cell derived from patients in the Bev group were analyzed for their capacity to produce IL10 as intracellular staining (Figure 5).”
BackgroundResveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells
Zhang, Y., Yang, S., Yang, Y., & Liu, T. (2019) · Infectious Agents and Cancer · doi:10.1186/s13027-019-0247-4 · Cited by 70
Zhao, S., Jiang, T., Zhang, L., Yang, H. J., Liu, X., Jia, Y., & Zhou, C. (2016) · Oncotarget · doi:10.18632/oncotarget.9130 · Cited by 53 · cited 1×
“A high percentage of Tregs is associated with a poor prognosis in different types of solid tumors [11,12].”
BackgroundNanodrug Delivery Systems for the Treatment of Ovarian Cancer
Pantshwa, J. M., Kondiah, P. P. D., Choonara, Y. E., Marimuthu, T., & Pillay, V. (2020) · Cancers · doi:10.3390/cancers12010213 · Cited by 53
Joly, F., Hilpert, F., Okamoto, A., Stuart, G. C. E., Ochiai, K., & Friedlander, M. L. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.03.019 · Cited by 50 · cited 1×
“Indeed, all these patients progressively develop pharmacoresistance for the majority of conventional chemotherapy drugs, and the only option left (if they are not eligible for phase I clinical trials) is to retreat them with previously adopted compounds [17].”
BackgroundBellati, F., Napoletano, C., Ruscito, I., Pastore, M., Pernice, M., Antonilli, M., Nuti, M., & Panici, P. B. (2009) · Investigational New Drugs · doi:10.1007/s10637-009-9351-4 · Cited by 48 · cited 2×
“Our results follow and confirm the original observation by our group [6] in which a significant reduction of Tregs and an increase in the proportion and function of effector CD8 T cells were found in an end-of-life ovarian cancer patient treated with low-dose intraperitoneal bevacizumab for malignant ascites.”
MethodResultSelf-citationAbajo, A., Boni, V., López, I., González-Huarriz, M., Bitarte, N., Rodríguez, J., Zárate, R., Bandrés, E., & García‐Foncillas, J. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.242 · Cited by 38 · cited 1×
“In addition, the decrease in IL-10 serum levels was confirmed to be even greater in response to bevacizumab treatment in metastatic colorectal cancer setting [28].”
BackgroundSerum cytokine levels in breast cancer patients during neoadjuvant treatment with bevacizumab
Jabeen, S., Zucknick, M., Nome, M., Dannenfelser, R., Fleischer, T., Kumar, S., Lüders, T., Gythfeldt, H. V. D. L., Troyanskaya, O. G., Kyte, J. A., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1457598 · Cited by 38 · cited 1×
“A similar finding was recently obtained in breast cancer neoadjuvant setting [27].”
ResultThomas, A. A., Fisher, J. L., Hampton, T. H., Christensen, B. C., Tsongalis, G. J., Rahme, G. J., Whipple, C. A., Steel, S. E., Davis, M. C., Gaur, A. B., et al. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1941-3 · Cited by 30
Palliative care in ovarian carcinoma patients—a personalized approach of a team work: a review
Segev, Y., Segev, L., Schmidt, M., Auslender, R., & Lavie, O. (2017) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-017-4484-8 · Cited by 19 · cited 1×
“Multi-treated progressive ovarian cancer still remains the most challenging disease setting for gynecologic oncologists, and so far, no global consensus has been met about how/how long patients should be continued to be treated [16].”
BackgroundChemotherapy in Recurrent Epithelial Ovarian Cancer (EOC): An Analysis of Prognostic Factors
Shamsunder, S., Kumar, L., Gupta, S., Kumar, S., Bhatla, N., Singh, R., & Kochupillai, V. (2000) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2000.tb01314.x · Cited by 5 · cited 1×
“) monochemotherapy (cisplatin) [7], while 10 other patients were identified as been treated with i.”
BackgroundNeoantigens from the bench to the bedside: new prospective for ovarian cancer immunotherapy
Napoletano, C., & Bellati, F. (2019) · Annals of Translational Medicine · doi:10.21037/atm.2019.10.62 · Cited by 4
Self-citation
Cited by
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Regulatory cells and the effect of cancer immunotherapy
Iglesias-Escudero, M., Arias-González, N., & Martínez-Cáceres, E. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01714-0 · Cited by 191
“Other approaches, such as blockade of TIM-3 [44], V-domain Ig suppressor of T cell activation (VISTA) [45, 46], treatment with glucocorticoid-induced TNFR-related (GITR) protein agonistic antibody [47, 48], anti-OX40 antibodies [49–51], IDO-1 inhibitors [52, 53], TGF-β inhibitors [54]VEGF-targeting therapy receptor 2…”
BackgroundTargeting oncogene and non-oncogene addiction to inflame the tumour microenvironment
Petroni, G., Buqué, A., Coussens, L. M., & Galluzzi, L. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00415-5 · Cited by 160
Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells
Zhang, Y., Yang, S., Yang, Y., & Liu, T. (2019) · Infectious Agents and Cancer · doi:10.1186/s13027-019-0247-4 · Cited by 70
Nanodrug Delivery Systems for the Treatment of Ovarian Cancer
Pantshwa, J. M., Kondiah, P. P. D., Choonara, Y. E., Marimuthu, T., & Pillay, V. (2020) · Cancers · doi:10.3390/cancers12010213 · Cited by 53
Metadata
- Authors
- Napoletano, C., Ruscito, I., Bellati, F., Zizzari, I. G., Rahimi, H., Gasparri, M. L., Antonilli, M., Panici, P. B., Rughetti, A., & Nuti, M.
- Affiliations
- Sapienza University of Rome (IT)
- Humboldt-Universität zu Berlin (DE)
- Azienda Ospedaliera Sant'Andrea (IT)
- Policlinico Umberto I (IT)
- Corresponding author
- Napoletano, Chiara
- ORCID
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2019-03-18
- Volume
- 8
- Issue
- 3
- Pages
- 380
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC6462947
- OpenAlex
- W2921909640
- Cited by
- 43
- References
- 34
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 5 · 2023: 4 · 2022: 8 · 2021: 8 · 2020: 4 · 2019: 3
- FWCI
- 5.50
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Associazione Italiana per la Ricerca sul Cancro (17432)
- Topics
- Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- bevacizumab, recurrent ovarian cancer, regulatory T cells, effector T cells, CD4+ T cells, CD8+ T cells, IL-10, tumor immune microenvironment, anti-angiogenic therapy, chemotherapy response, peripheral blood mononuclear cells, combination immunotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.